In the EU alone, approximately 30 million people are affected by a rare disease, many of them children. Most of the 6,000 to 8,000 rare diseases known to date are caused by the altered function of a single gene (Boycott&Ardigó, 2018). This project under the supervision of Prof. Christoph Klein aims to develop innovative strategies for precision medicine in rare diseases by (i) re-wiring aberrant molecular networks for therapeutic purposes and (ii) identifying novel “druggable” targets using CRISPR-Cas9-mediated genome-wide screens.

Anelloviruses are a diverse group of ubiquitous viruses infecting humans and vertebrates. Their contribution to disease development remains elusive. We hypothesize that during lifelong, persistent infection disbalances in the viral community can drive onset and progression of disease, e.g. cancer. We aim at a thorough description of the viral spectrum present in healthy and diseased tissue by high-throughput screening of sequencing data and subsequent identification of viral variants correlated with pathogenesis.